# Exagen Inc. Reports First Quarter 2026 Results
Canonical URL: https://biopharmsignal.com/news/XGN/exagen-inc-reports-first-quarter-2026-results
Ticker: XGN
Company: Exagen
Source: Exagen
Published: 2026-05-11 12:00 EST
Original Source URL: https://investors.exagen.com
## Summary

Delivers record total revenue and AVISE(R) CTD average selling price CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026, and recent corporate updates.

## Article Body
Delivers record total revenue and AVISE(R) CTD average selling price CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026, and recent corporate updates.
## Recent Company News
- 2026-06-01 13:00 EST — [Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus](https://biopharmsignal.com/news/XGN/exagen-announces-publication-of-systematic-review-confirming-robust-real-world-performance-of-avise-lupus) — Source: Exagen
- 2026-05-11 12:00 EST — [Exagen Inc. Reports First Quarter 2026 Results](https://biopharmsignal.com/news/XGN/exagen-inc-reports-first-quarter-2026-results) — Source: Exagen
- 2026-04-27 13:00 EST — [Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026](https://biopharmsignal.com/news/XGN/exagen-inc-to-announce-first-quarter-financial-results-on-may-11-2026) — Source: Exagen
- 2026-03-10 12:00 EST — [Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results](https://biopharmsignal.com/news/XGN/exagen-inc-reports-strong-fourth-quarter-and-full-year-2025-results) — Source: Exagen
- 2026-03-03 14:00 EST — [Exagen Inc. to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/XGN/exagen-inc-to-participate-in-upcoming-investor-conferences) — Source: Exagen
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)